- Pin
- 🎁 12th Anniversary Celebration – Reward Distribution Notification
🎊 Congratulations to all winners! Rewards have been sent to your Gate accounts. Please check your balances
Note:
- In regions where shipping isn’t available, physical merch will be converted to equivalent vouchers — please be patient;
- If an item is out of stock, it will be substituted with merch of equal value.
🚀 Thank you for your support! Stay tuned for more exciting events
- 【Gate Daily Market Digest】📊
Unlock today’s key crypto market insights at a glance!
Top Gainers⭐️ $SNAKEAI $YBDBD $BASEPTL $FPFT $TMAI
Trending Coins🔥 $YBDBD $LAUNCHCOIN $SPX $MIRAI $ANIME
#FearGreedIndex# #TopGainers#
- #May CPI Incoming#
This Wednesday, the U.S. will release May CPI data — a key test for rate cut expectations. Cleveland Fed forecasts 2.4% YoY CPI (up from 2.3%), with core CPI flat.
💬 If inflation beats expectations, will the Fed still cut in June? Will you stay on the sidelines or take early action?
#Tech Giants Eye Stablecoins#
Apple, Google, Airbnb, and X are in talks to integrate stablecoins into their payment systems, aiming to cut fees and streamline global payments. Following Circle’s IPO surge, stablecoins are quickly gaining traction across tech and finance.
💬 Could stablecoins be - Trading Myth vs Reality: Rising Wedge
❌ Myth
"A rising wedge is a bullish signal; buy immediately once the pattern completes."
✅ Reality
Proper rising wedge trading requires confirmation:
1.A clear break below the lower line (2 confirmed closes)
2.Volume increase on the break
3.A pullback that doesn't break above the lower line
💡 How to trade correctly:
· Wait for the pullback after the break
· Set stop-loss above the upper line
· If price breaks above upper line, volume must confirm or it's a false breakout
- What are Gate Post Ambassadors? One article guides you through the responsibilities and benefits of being a Gate Post ambassador!👇️
The first three common De-Da-Botu monoclonal antibody has been approved in Japan for the treatment of breast cancer.
On December 28, Jinshi Data reported that on December 27, local time, The First Three Company announced that the targeted TROP2 antibody-drug conjugate (ADC) DATROWAY® (trastuzumab deruxtecan) developed by the company in collaboration with AstraZeneca has been approved in Japan for the treatment of adult patients with unresectable or recurrent breast cancer who are hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), and have an immunohistochemistry (IHC) score of 0, 1+, or 2+ with in situ hybridization (ISH-) after receiving chemotherapy.